In 2009, the Brazilian National Tuberculosis Program recommended changing the regimen for the treatment of sensitive tuberculosis by replacing RHZE with RHZ, involving reduced doses of isoniazid and pyrazinamide in a fixed-dose combination formulation. The process of change was made possible by the financial, political and technical support that ensured national drug provision and the training of healthcare professionals. In this analysis of the Brazilian case, we present the lessons learned with the implementation process and we formulate recommendations for the sustainability of this and other future technological innovations in the diagnosis, prevention and treatment of tuberculosis.
Fixed Dose Combination; Public Health; Tuberculosis